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============

Before the completion of the Human Genome Project, the genome was expected to contain at least 100,000 protein-coding genes. DNA sequencing, however, revealed that only about 21,000 such genes can be found within the approximately 3 billion DNA bases. Although approximately 76 % of the human genome is transcribed, less than 3 % encodes for proteins \[[@CR1]\]. The remaining 97 % were thought to be 'junk' DNA as these sequences are not translated into protein and were not known to encode relevant information with the exception of few non-coding RNAs such as transfer or ribosomal RNAs. This assumption was based on the central dogma of molecular biology postulated by Francis Crick in 1958, which states that all relevant biological information flows unidirectionally from DNA to mRNA to protein \[[@CR2]--[@CR4]\]. As the number of protein-coding genes was unexpectedly low and similar to much simpler organisms, it was not immediately clear how the high degree of human complexity could derive from such a small protein repertoire. Additionally, the proteomes of higher organisms have been shown to be relatively stable, with humans and mice sharing 99 % of their protein-coding genes. Though mechanisms like alternative splicing can increase the variation of the protein repertoire, today, the complexity of the regulatory network of non-coding RNAs, i.e. the control architecture of the system, is thought to be the main source of diversity \[[@CR5], [@CR6]\]. This is supported by the fact that while there is only a small increase in the number of protein-coding genes in humans as compared to the nearly 19,000 protein-coding genes in the nematode *Caenorhabditis elegans*, the ratio of non-protein coding to protein-coding sequences is almost 17-fold higher in humans \[[@CR6], [@CR7]\]. MicroRNAs (miRNAs) represent one subgroup of non-coding RNAs. More than 2000 miRNAs are encoded in the human genome, but only about 400 miRNAs can be found in *C. elegans* (<http://www.mirbase.org/>). The miRNA system is also highly evolutionarily conserved: 196 miRNA families are conserved among mammals and 34 miRNA families from *C. elegans* are conserved in humans with few examples of secondary loss and very low levels of nucleotide substitutions to the primary sequence \[[@CR8], [@CR9]\]. Epigenetic control mechanisms, including miRNAs that temporarily modulate gene expression, allow the cell to respond quickly to environmental changes as messenger RNA (mRNA) molecules can be targeted for degradation or blocked from translation into proteins \[[@CR10]\].

Biogenesis and Function of miRNAs {#Sec2}
=================================

miRNAs are one of the largest gene families \[[@CR11]\]. Due to their mode of operation, they have the potential to target approximately 60 % of human genes and thereby influence many biological pathways \[[@CR12], [@CR13]\]. miRNAs are expressed in a temporal and tissue-specific manner \[[@CR14]\], e.g. miR-208a can only be found in cardiomyocytes \[[@CR15]\] and the miRNA content in different cells can vary from 1 to more than 30,000 copies \[[@CR16]\]. miRNAs play an important role in the regulation of embryonic development as well as in adult life with distinct expression profiles in every cell type at each developmental stage \[[@CR17]\]. They show dynamic and site-specific expression patterns during embryogenesis and suppression leads to death during early gestation \[[@CR18], [@CR19]\]. The first miRNA was identified in 1993 during the study of *C. elegans* mutants that exhibited abnormal developmental timing. The gene responsible for this phenotype, *lin*-*4*, did not code for a protein but for two small RNAs with complementary sequences to the 3′-untranslated region of the *lin*-*14* mRNA. *Lin*-*4* had been shown previously to negatively regulate the protein level of LIN-14, creating a temporal decrease in LIN-14 during postembryonic development that regulates the execution of stage-specific larval programmes \[[@CR2], [@CR20], [@CR21]\]. A similar mechanism of RNA silencing had been known in plants since the beginning of the 1990s \[[@CR22]\], but as *lin*-*4* was not detected in other species, this new mechanism was believed to be a process occurring only in nematodes. However, in the year 2000, *let*-*7*, that also coordinates developmental timing in C. *elegans*, was discovered. *Let*-*7* codes for a 21-nucleotide non-coding RNA transcript that negatively regulates the mRNA of *lin*-*41* through complementary Watson-Crick base pairing at the 3′-UTR and therefore influences gene expression in a way similar to *lin*-*4* \[[@CR19]\]. Unlike *lin*-*4*, the sequence of *let*-*7* was found to be conserved in a wide range of species including vertebrates, making the biological significance of this finding apparent \[[@CR4], [@CR23]\]. Since then, over 25,000 miRNAs have been identified from more than 190 different species including algae, plants, nematodes, protozoa, viruses or vertebrates \[[@CR4]\].

MiRNA genes are located in different parts of the human genome and hence show a great variation in their transcriptional regulation and expression patterns \[[@CR24]\]. The majority of human miRNAs are co-expressed with their host gene within intronic sequences of protein-coding genes, while others are transcribed independent of coding genes \[[@CR13]\]. More than 40 % of human miRNAs appear in clusters and are transcribed together, forming a transcript that contains multiple miRNA sequences \[[@CR25]\]. After transcription by mainly RNA polymerase II \[[@CR26]\], the primary miRNA (pri-miRNA) is processed by the RNase III Drosha, into a stem-loop precursor of \~70 nucleotides, the so called pre-miRNA \[[@CR27]\] (Fig. [1](#Fig1){ref-type="fig"}). As Drosha by itself cannot bind pri-miRNAs sufficiently, it interacts with the cofactor DGCR8, forming the microprocessor complex \[[@CR28]\]. The pre-miRNA is then exported to the cytoplasm in a Ran-GTP dependent manner by Exportin-5 that specifically binds the pre-miRNA \[[@CR29]\]. Once it has reached the cytoplasm, the pre-miRNA is cleaved by the RNaseIII Dicer together with the cofactor TRBP \[[@CR30], [@CR31]\] and PACT \[[@CR32]\] into a duplex, consisting of two miRNA strands \[[@CR33]\]. After transcription, the individual miRNAs can be additionally regulated by adenosine deaminases that convert adenosine to inosine and thereby influence the hybridisation of miRNAs to their targets \[[@CR34]\]. The RNA duplex is subsequently loaded onto an Argonaute protein, together forming the RNA-induced silencing complex (RISC). After the duplex has been unwound, one of the strands is released and in most cases degraded. The other strand guides the RISC to miRNA response elements (MRE) of the target gene that are complementary to its sequence \[[@CR4], [@CR8]\]. MiRNAs mainly target mRNAs, but also have the potential to bind to a wide variety of other molecules including tRNAs or rRNAs \[[@CR35]\]. Each miRNA locus produces two mature miRNAs, the 'guide' strand with a prevalence of 96--99 % and the 'passenger' miRNA\* strand \[[@CR8]\]. miRNA strand selection depends on different factors including the thermodynamic stability at the ends of the miRNA:miRNA\* duplex \[[@CR36], [@CR37]\]. Though the miRNA\* strand is usually degraded, in some cases, both strands can be functional \[[@CR37]\] with either overlapping or different target sites \[[@CR38]\]. miRNA\*-sequences are likely to have functional relevance in small RNA regulatory networks, as they are highly evolutionary conserved with e.g. more than 40 % of miRNA\*-sequences resisting nucleotide divergence across *Drosophila* evolution \[[@CR39]\]. Given that both the 'mature' and the 'passenger' strands can be functional, the miRNA/miRNA\* nomenclature has now been retired and instead, the two sequences are referred to as 5-p or 3-p strand of the respective miRNA.Fig. 1Schematic diagram of miRNA biogenesis and proposed mechanisms for miRNA function. MiRNAs can affect protein expression by inducing an Ago-mediated cleavage of the mRNA, or destabilisation and degradation of mRNA by deadenylation, translational inhibition and sequestration of mRNAs in P-bodies. Adapted from \[[@CR4], [@CR75], [@CR76]\]

Once they have bound to their target mRNA, miRNAs are able to regulate gene expression in different and sometimes opposite ways depending on factors such as the degree of complementarity with the target mRNA. Near-perfect complementarity of miRNAs and their targets which mainly occurs in plants leads to direct cleavage of the target mRNA \[[@CR40]\]. In animals, however, target recognition in most cases does not require perfect complementarity but mainly depends on pairing to the 'miRNA seed', the nucleotides 2--8 of the 5′ portion of the miRNA \[[@CR41]\]. The short seed match and incomplete base pairing enable the miRNA to target different RNA molecules while a single target gene can contain multiple conserved regions of complementarity \[[@CR41], [@CR42]\]. The predominant mechanism by which miRNAs reduce protein output is by triggering deadenylation of the target mRNA, which makes the mRNA more susceptible to degradation \[[@CR43]\]. Additionally, miRNAs can inhibit eukaryotic initiation factors \[[@CR44]\] or interfere with translational elongation \[[@CR45]\]. In some cases, the miRNA response has been reported to switch from inhibition of gene expression to enhancement, thereby e.g. inducing up-regulation of target mRNAs on cell cycle arrest and repressing translation in proliferating cells \[[@CR4], [@CR46]\]. These characteristics create a complex regulatory control network that changes in relation to age, developmental or pathophysiological state of the cell, and involves multiple cooperative effects on a large number of targets enabling miRNAs to control various pathways at different levels \[[@CR47]\].

Circulating MiRNAs {#Sec3}
==================

The majority of miRNAs are located intracellularly. In 2007, however, miRNAs were found in exosomes, in which they were delivered to other cells allowing gene-based communication between cells \[[@CR48]\]. Sequence motifs present in miRNAs can thereby enable specific interaction and loading into exosomes \[[@CR49]\]. This transfer of RNA through exosomes might enable local and systemic intercellular exchange of biological information \[[@CR48]\]. In the following years, miRNAs were detected in most extracellular biological fluids including serum, plasma, saliva and urine where they showed distinct compositions \[[@CR50]\]. MiRNAs can be released into the blood circulation by various mechanisms, including active secretion, apoptosis or necrosis. These miRNAs circulate in different types of vesicles, such as apoptotic bodies, microvesicles (100--1000 nm), exosomes (50--100 nm) and lipoproteins \[[@CR51]\]. Many extracellular miRNAs in circulation, however, are also independent of vesicles and are associated with RNA-binding proteins like Argonaute 2 protein, a part of the RNA-induced silencing complex \[[@CR52]\]. Human miRNAs isolated from plasma are highly stable in boiling water and resistant to very high or low pH, prolonged room temperature incubation or repeated freeze-thawing \[[@CR53]\]. Compared to endogenous plasma miRNAs, synthetic miRNAs are rapidly degraded when added to human plasma unless the RNase activity was inactivated beforehand \[[@CR54]\]. Therefore, though miRNAs are susceptible to degradation, circulating miRNAs are resistant to RNase activity as they are secreted in a complex with other molecules such as Argonaute proteins or lipoproteins or in membrane-derived vesicles \[[@CR53]\].

Deregulated levels of circulating miRNAs have been linked to different disease states \[[@CR24]\]. During cellular stress or pathophysiological conditions such as hypoxia, miRNAs can provide an efficient way of gene regulation to allow the cells to adopt and recover \[[@CR55]\]. As they are disease-specifically modulated and easily accessible, circulating miRNAs are potential blood-based biomarkers, useful for diagnostic application e.g. in screening programmes and for monitoring of treatment response or outcome prediction \[[@CR4], [@CR51]\]. Based on their biology, circulating miRNAs may have a high level of sensitivity and specificity allowing early and reliable detection of pathological states \[[@CR47]\]. Arguably, miRNAs offer some advantages over the most commonly used biomarkers \[[@CR56]\]: miRNAs are often expressed in a tissue-, development- or disease-specific manner and the circulating levels of miRNAs are reproducible and consistent among individuals of the same species \[[@CR51], [@CR57]\]. Compared to numerous serum proteins, including various processing variants, and posttranslationally modified proteins, there are far fewer known miRNA species, making it possible to obtain a comprehensive profile. In addition, due to their small size and chemical composition, miRNAs are less complex than most other biological molecules and more stable in plasma than mRNAs \[[@CR57]\]. Also, miRNAs can be quantified cost-effectively using real-time polymerase chain reaction and a profile can be obtained by next-generation sequencing or microarrays.

MiRNAs as Biomarkers for Coronary Heart Disease {#Sec4}
===============================================

An example for the potential use of miRNAs as biomarkers is the detection of myocardial infarction, where they might complement the existing biomarkers, such as cardiac troponins. There is still a need for novel biomarkers, as troponins fail to rule out myocardial infarction immediately on admission and are not reliable in certain groups of patients \[[@CR51], [@CR53]\]. Another major limitation is their lack of specificity, as unspecific elevation of troponin levels can be caused by non-ischemic conditions such as heart failure and renal disease \[[@CR58]\]. MiRNAs that are specifically expressed in the heart muscle, like miR-208a, which is involved in the regulation of myosin heavy chain production during cardiac development \[[@CR15]\], have the potential to improve diagnosis of myocardial infarction. In a study with 33 consecutive AMI and 30 non-AMI patients that presented with chest pain, miR-208a remained undetectable in plasma of non-AMI patients including patients with chronic renal failure or trauma, but it was initially detected in 90.9 % of AMI patients and in 100 % of AMI patients within 4 h of the onset of chest pain, even in patients where cardiac troponin I (cTnI) levels were not yet affected \[[@CR59]\]. This earlier miRNA peak might be caused by a faster release of miRNAs from damaged cardiomyocytes, as miRNAs are mainly bound to protein complexes in the cytosol while most of the cTnI is bound to myofibrils \[[@CR60]\]. An overview of miRNA studies on coronary heart disease and myocardial infarction has been published elsewhere \[[@CR61], [@CR62]\]. A major shortcoming of the current literature is the lack of large cohort studies (Table [1](#Tab1){ref-type="table"}). Few prospective studies on coronary heart disease have been published to date \[[@CR63]\]. Instead, circulating miRNAs have been measured in numerous small case--control studies without adequate consideration of the effects of comorbidities \[[@CR64]\] and medication \[[@CR61], [@CR62]\].Table 1Selected studies on circulating miRNAs and coronary heart disease (CHD)First authorDescription of study populationStudy sizeNo. of miRNAsNormalisationAdditional correlationsWang et al. \[[@CR59]\]Patients with AMI vs patients with non-MI CHD vs patients with other CVD33 vs 16 vs 174*Cel*-*miR*-*39*cTnIChen et al. \[[@CR77]\]Patients with CHD851*Cel*-*miRs*IL-1β, endothelium-dependent flow-mediated vasodilationJansen et al. \[[@CR78]\]Patients with stable CAD, 6-year follow-up18110*Cel*-*miR*-*39*Circulating MVs, exosomes, vesicle-free plasmaHuang et al. \[[@CR79]\]Patients with AMI vs healthy controlsI: 178 vs 198\
II: 150 vs 1502*Cel*-*miR*-*39*CK, CKMB, cTnI\
Heparinised patients were excludedFinn et al. \[[@CR80]\]Patients with significant CHD vs patients with only CHD risk factors vs healthy subjects21 vs 20 vs 278miR-346Circulating MPsLiebetrau et al. \[[@CR81]\]Patients with HOCM, before/after TASH214*Cel*-*miR*-*39*hs-cTnTDe Rosa et al. \[[@CR82]\]Patients with stable CAD vs patients with ACS vs patients without CAD31 vs 19 vs 77*Cel*-*miR*-*39*hsTnTFichtlscherer et al. \[[@CR68]\]Patients with CAD vs healthy controlsI: 36 vs 17\
II: 31 vs 148*Cel*-*miR*-*39*-Wang et al. \[[@CR83]\]Patients with AMI vs patients with angina pectoris vs control subjects13 vs 176 vs 1271U6cTnIOrlemans et al. \[[@CR84]\]Patients with ACS vs controls106 vs 2265RNU6cTnI, hs-TnT*CVD* cardiovascular disease, *CAD* coronary artery disease, *ACS* acute coronary syndrome, *HOCM* hypertrophic cardiomyopathy, *TASH* transcoronary ablation of septal hypertrophy, *MV* microvesicles, *MP* microparticles, *CK* creatine kinase, *cTnI* cardiac troponin I, *cTnT* cardiac troponin T

Statins, for example, reduce the circulating levels of the liver-derived miRNA, miR-122 \[[@CR65]•\]. Our study by Willeit and Zampetaki et al. \[[@CR66]••\] identified circulating platelet miRNAs that are responsive to antiplatelet therapy. In healthy volunteers, prolonged platelet inhibition over 4 weeks affected the levels of plasma miRNAs and resulted in a reduction of several miRNAs, including miR-126 (*P* \< 0.001), miR-150 (*P* = 0.003), miR-191 (*P* = 0.004), and miR-223 (*P* = 0.016). Similar results were obtained in patients with symptomatic carotid atherosclerosis (*n* = 33) who were on 75-mg aspirin (ASA) at baseline. After initiation of dual antiplatelet therapy with either dipyridamole or clopidogrel, miRNA changes were observed after 48 h. An effect of ASA on miR-126 plasma levels was also demonstrated by de Boer et al. \[[@CR67]•\]. Although the miRNA content of platelets is low compared with other cells, platelets contribute substantially to the circulating miRNA pool. Antiplatelet therapy was a likely confounding factor in previous case--control studies reporting a loss of miRNAs in patients with coronary artery disease \[[@CR62], [@CR68]\].

Similarly, heparin, used in interventional cardiology, is another potentially confounding factor that may influence miRNA measurements due to its known interference with polymerase chain reactions \[[@CR69], [@CR70]\]. In the study by Kaudewitz et al. \[[@CR71]•\], platelet-poor plasma was obtained from patients undergoing cardiac catheterisation for diagnostic coronary angiography, or for percutaneous coronary intervention, both before and after heparin administration. Heparin had pronounced effects on the assessment of the exogenous *C. elegans* spike-in control (decrease by approx. 3 cycles), which disappeared 6 h after the heparin bolus. Measurements of endogenous miRNAs were less sensitive to heparin medication. Similar findings were reported by Boeckel and colleagues \[[@CR72]•\]. Kaudewitz et al. \[[@CR71]•\] suggested a potential solution for measuring miRNAs more accurately in heparinized patients: normalisation of individual miRNAs with the average cycle threshold value of all miRNAs provided a suitable alternative to normalisation with exogenous *C. elegans* spike-in control in this setting (Fig. [2](#Fig2){ref-type="fig"}). Thus, both the timing of blood sampling relative to heparin dosing and the normalisation procedure are critical for reliable miRNA measurements in patients receiving intravenous heparin. Otherwise, the rise in circulating miRNAs post myocardial infarction can be misinterpreted as novel biomarkers for myocardial injury, whereas the elevation in patients compared to controls may, at least in part, be attributable to the heparin-induced suppression of the exogenous *C. elegans* normalisation control commonly used in miRNA measurements \[[@CR73]\].Fig. 2Normalisation of miRNA measurements. Platelet-poor EDTA plasma was collected from patients undergoing percutaneous coronary intervention (PCI, *n* = 20) at four time points: before heparin administration (TP-pre), 5 min after heparin administration but just prior to stent deployment (TP-0 min), and 30 and 360 min after stent deployment (TP, 30 min and TP, 360 min). Additional samples were obtained from patients undergoing cardiac catheterisation for diagnostic purposes (Dx) with (*n* = 7) and without (*n* = 10) heparin administration. Note the discrepancies at TP 0 min and TP 30 min with the conventional normalisation of miRNA measurements using an exogenous *C.elegans* spike-in control (*Cel*-miR *39*, *left panel*) compared to the normalisation using the average cycle threshold (Ct) value of a panel of endogenous miRNAs (*right panel*). Reproduced with permission from \[[@CR71]•\]

Conclusions {#Sec5}
===========

In summary, medication is an important confounding factor when investigating the relation of circulating miRNAs with coronary heart disease (Fig. [3](#Fig3){ref-type="fig"}). Some effects may also apply to measurements in full blood \[[@CR74]\]. Future studies will need to address these shortcomings of the early literature on miRNA biomarkers and overcome confounding factors of miRNA measurements to assess the clinical utility of miRNA biomarkers in coronary heart disease.Fig. 3Confounding of miRNA measurements by medication. Antiplatelet medication and statins reduce the endogenous levels of platelet- and liver-derived miRNAs, respectively. Heparin predominantly affects the exogenous spike-in controls commonly used for normalisation. Yet, most case--control studies on miRNA biomarkers for coronary heart disease did not adjust or adequately control for the effects of medication
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